SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis - Takeaways - MDSpire

SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis

A nationwide cohort study found lower rates of cardiorenal complications and hepatic decompensation

  • By

  • Henry Thomas

  • March 10, 2026

  • 2 min

Share

  • 1

    SGLT2 inhibitors were linked to lower risks of kidney, cardiovascular, and hepatic complications in patients with type 2 diabetes and cirrhosis.

  • 2

    The study analyzed data from 24,259 patients, comparing outcomes between those treated with SGLT2 inhibitors and DPP-4 inhibitors.

  • 3

    Patients treated with SGLT2 inhibitors had a significantly reduced risk of end-stage kidney disease and acute kidney injury.

  • 4

    Major adverse cardiovascular events were less frequent in patients receiving SGLT2 inhibitors compared to those on DPP-4 inhibitors.

  • 5

    Fewer hepatic decompensation events were observed in patients treated with SGLT2 inhibitors, suggesting potential benefits for this population.

Original Source(s)

SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis

  • by Henry Thomas

  • March 10, 2026

Related Content

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.

Makary Resigns as FDA Commissioner Following Policy Disputes

Transition follows disputes over vaccine policy, food additive regulation, and flavored vaping product authorization

Postop Pain Differs by Vitamin D Status

Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.